

Keisuke Ueki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2149454/publications.pdf>

Version: 2024-02-01

41
papers

2,723
citations

516710

16
h-index

477307

29
g-index

43
all docs

43
docs citations

43
times ranked

2970
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression profiling of 19q-loss astrocytomas suggest a specific pattern associated with the better prognosis. <i>Journal of Neuro-Oncology</i> , 2021, 154, 221-228.	2.9	0
2	The Japan Neurosurgical Database: Statistics Update 2018 and 2019. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 675-710.	2.2	8
3	Intracranial subarachnoid hemorrhage caused by an aneurysm at the thoracic spinal region: case report and literature review. <i>British Journal of Neurosurgery</i> , 2020, 34, 672-676.	0.8	6
4	Middle Cerebral Artery Aneurysm Associated with Moyamoya Disease. <i>World Neurosurgery</i> , 2020, 140, 233-236.	1.3	3
5	The Japan Neurosurgical Database: Overview and Results of the First-year Survey. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 165-190.	2.2	13
6	Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. <i>European Journal of Endocrinology</i> , 2020, 183, K7-K12.	3.7	13
7	Untying the Gordian Knot : Why Glioblastomas are Still Incurable, and How Can We overcome the Hurdles. <i>Japanese Journal of Neurosurgery</i> , 2020, 29, 198-203.	0.0	0
8	NIMG-29. DEVELOPING AUTOMATIC SEGMENTATION METHOD FOR BRAIN TUMOR MR IMAGES THAT CAN BE USED AT MULTIPLE FACILITIES. <i>Neuro-Oncology</i> , 2020, 22, ii153-ii154.	1.2	0
9	PATH-08. EVALUATION OF MISMATCH REPAIR GENE EXPRESSION BY IMMUNOHISTOCHEMISTRY MAY DETECT EARLY PHASE OF MMR DEFICIENCY IN RECURRENT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii165-ii165.	1.2	0
10	PATH-10. EFFECTS OF 19q-LOSS IN IDH-MUTATED ASTROCYTOMAS ON BETTER PROGNOSIS AND OLIGODENDROGLIOMA-LIKE MORPHOLOGY. <i>Neuro-Oncology</i> , 2020, 22, ii165-ii166.	1.2	0
11	Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. <i>Cancer Immunology Research</i> , 2019, 7, 1148-1161.	3.4	56
12	DNA demethylation is associated with malignant progression of lower-grade gliomas. <i>Scientific Reports</i> , 2019, 9, 1903.	3.3	31
13	PATH-37. PROGNOSTIC ROLE OF TERT PROMOTER MUTATIONS IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi151-vi151.	1.2	0
14	10070: MET-02 NON-SMALL-CELL LUNG CANCER WITH SYNCHRONOUS BRAIN METASTASIS IN THE ERA OF MOLECULAR TARGETED DRUGS: TREATMENT OUTCOME AND RISK FACTORS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii35-ii35.	0.7	0
15	Brain invasion by chronic lymphocytic leukemia. <i>Neuropathology</i> , 2019, 39, 54-57.	1.2	5
16	Histology of hemangioblastoma treated with stereotactic radiosurgery confirms its effectiveness. <i>Journal of Clinical Neuroscience</i> , 2018, 51, 43-45.	1.5	2
17	Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. <i>Journal of Neurosurgery</i> , 2018, 128, 1428-1437.	1.6	36
18	IMMU-58. REDUCED NEOANTIGEN EXPRESSION AS A POSSIBLE IMMUNE EVASION MECHANISM DURING GLIOMA PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi134-vi134.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Intravascular Lymphoma with an Acute Course of Cerebellar Hemorrhage: A Case Report. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 96-100.	2.2	2
20	<i>IDH</i> -mutated astrocytomas with 19q loss constitute a subgroup that confers better prognosis. <i>Cancer Science</i> , 2018, 109, 2327-2335.	3.9	20
21	Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. <i>Acta Neuropathologica</i> , 2017, 133, 445-462.	7.7	64
22	Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system. <i>Neuro-Oncology</i> , 2017, 19, 1228-1236.	1.2	26
23	Genetic and epigenetic stability of oligodendrogliomas at recurrence. <i>Acta Neuropathologica Communications</i> , 2017, 5, 18.	5.2	47
24	Distinct molecular profile of diffuse cerebellar gliomas. <i>Acta Neuropathologica</i> , 2017, 134, 941-956.	7.7	40
25	Classification of adult diffuse gliomas by molecular markers—a short review with historical footnote. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 2-6.	1.3	10
26	GENE-60. INTEGRATED GENOMIC AND EPIGENOMIC ANALYSIS FOR HEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM. <i>Neuro-Oncology</i> , 2017, 19, vi106-vi106.	1.2	0
27	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. <i>Acta Neuropathologica Communications</i> , 2016, 4, 79.	5.2	189
28	MPT-02 MOLECULAR CLASSIFICATION BASED ON IDH1/2 AND TERT PROMOTER WELL-DEFINES SUBGROUPS WITH DIFFERENT OUTCOME IN ADULT DIFFUSE GLIOMAS: A REPORT FROM GLIOMA MOLECULAR CLASSIFICATION CONSORTIUM. <i>Neuro-Oncology</i> , 2015, 17, v138.2-v138.	1.2	0
29	Significance of <i>IDH</i> mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. <i>Cancer Science</i> , 2012, 103, 587-592.	3.9	87
30	Metastatic brain sarcoma with gliomatous component. <i>Brain Tumor Pathology</i> , 2011, 28, 365-369.	1.7	0
31	Polar spongioblastoma: A high-grade glioma that does not contain the IDH1 mutation or 1p/19q LOH. <i>Neuropathology</i> , 2010, 30, 547-552.	1.2	2
32	Characteristics of Intramedullary Subependymoma. <i>Spinal Surgery</i> , 2010, 24, 100-102.	0.0	3
33	Adjuvant Therapy for Child-bearing Aged Women with Oligodendroglioma : Recommendations based on available Evidence(<SPECIAL ISSUE>Management of Pregnancy and Delivery in Neurosurgical) <i>Tj ETQq1 1 0.7846.14 rgBT (/Overlock 10 Tf 50 1</i>	0.0	0
34	3.Molecular Genetic Analysis and Diagnosis of Gliomas(Morning Seminar-13 Pathophysiological) <i>Tj ETQq0 0 0 rgBT (/Overlock 10 Tf 50 1</i>	0.0	0
35	Oligodendroglioma: Impact of molecular biology on its definition, diagnosis and management. <i>Neuropathology</i> , 2005, 25, 247-253.	1.2	19
36	Selective Expression of a Subset of Neuronal Genes in Oligodendroglioma with Chromosome 1p Loss. <i>Brain Pathology</i> , 2004, 14, 34-42.	4.1	57

#	ARTICLE	IF	CITATIONS
37	Primary spinal oligoastrocytoma: a case report. <i>World Neurosurgery</i> , 2004, 61, 77-81.	1.3	15
38	Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. <i>Oncogene</i> , 2002, 21, 3961-3968.	5.9	80
39	Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. <i>Clinical Cancer Research</i> , 2002, 8, 196-201.	7.0	104
40	Silencing of the caspase-1 gene occurs in murine and human renal cancer cells and causes solid tumor growth in vivo. <i>International Journal of Cancer</i> , 2001, 91, 673-679.	5.1	24
41	Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1473-1479.	6.3	1,759